Rein Therapeutics Inc (RNTX)

NASDAQ
Currency in USD
1.8200
-0.0600(-3.19%)
Closed·
After Hours
1.82000.0000(0.00%)
·
RNTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RNTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.80001.9400
52 wk Range
1.35004.4000
Key Statistics
Edit
Prev. Close
1.88
Open
1.94
Day's Range
1.8-1.94
52 wk Range
1.35-4.4
Volume
10.69K
Average Volume (3m)
35.03K
1-Year Change
-41.61%
Book Value / Share
0.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RNTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.0000
Upside
+284.62%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Rein Therapeutics Inc News & Analysis

Show more

Rein Therapeutics Inc Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Compare RNTX to Peers and Sector

Metrics to compare
RNTX
Peers
Sector
Relationship
P/E Ratio
−0.7x−4.3x−0.5x
PEG Ratio
−0.060.000.00
Price/Book
8.3x2.1x2.6x
Price / LTM Sales
-26.4x3.1x
Upside (Analyst Target)
260.8%169.0%51.1%
Fair Value Upside
Unlock0.8%8.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.0000
(+284.62% Upside)

Earnings

Latest Release
Apr 07, 2025
EPS / Forecast
-2.16 / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RNTX Income Statement

FAQ

What Is the Rein Therapeutics (RNTX) Stock Price Today?

The Rein Therapeutics stock price today is 1.82

What Stock Exchange Does Rein Therapeutics Trade On?

Rein Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Rein Therapeutics?

The stock symbol for Rein Therapeutics is "RNTX."

What Is the Rein Therapeutics Market Cap?

As of today, Rein Therapeutics market cap is 39.89M.

What Is Rein Therapeutics's Earnings Per Share (TTM)?

The Rein Therapeutics EPS (TTM) is -2.87.

From a Technical Analysis Perspective, Is RNTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Rein Therapeutics Stock Split?

Rein Therapeutics has split 1 times.

How Many Employees Does Rein Therapeutics Have?

Rein Therapeutics has 11 employees.

What is the current trading status of Rein Therapeutics (RNTX)?

As of 16 Jun 2025, Rein Therapeutics (RNTX) is trading at a price of 1.82, with a previous close of 1.88. The stock has fluctuated within a day range of 1.80 to 1.94, while its 52-week range spans from 1.35 to 4.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.